Yi-Hao Lin¹, Ilene Chen² and Ling-Hong Tseng¹

¹Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital and University of Chang Gung School of Medicine, Taiwan. ²School of Electrical and Information Engineering, University of Sydney, Australia.  

Abstract

Fesoterodine extended-release (brand name Toviaz) is a new competitive muscarinic receptor antagonist labeled for the treatment of overactive bladder (OAB). Here we have undertaken a substantial update to a systematic review evaluating the effects of fesoterodine in the treatment of OAB. Our results indicate that fesoterodine was found to have significant improvements in the management of OAB symptoms compared with placebo. Post hoc analysis of these trials demonstrated significant improvements in health-related quality of life in patients with overactive bladder. Only one study included tolterodine, and direct comparisons between fesoterodine and tolterodine were not conducted. The most common treatment-emergent adverse effects associated with fesoterodine included dry mouth and constipation. In summary, fesoterodine appears to be effective and generally safe for the treatment of overactive bladder. Nonetheless, additional comparative trials are required to evaluate whether fesoterodine provides a substantial advantage over extended-release tolterodine.

Presentation

• Pages: 11

• References: 35
  

• Tables and figures: 2